树突状细胞肿瘤疫苗的研究进展  

Progress in Dendritic Cell Tumor Vaccines in Cancer Immunotherapy

作　　者：高建勇[1] 王兴龙[2] 闫广谋[1] 段小宇[1] 马云志[1] 

机构地区：[1]吉林大学畜牧兽医学院,吉林长春130062 [2]军事医学科学院军事兽医研究所,吉林长春130062

出　　处：《生物技术通讯》2007年第3期486-489,共4页Letters in Biotechnology

摘　　要：树突状细胞(DC)是目前发现的抗原提呈功能最强的专职抗原提呈细胞。大量实验已证明DC疫苗在抗肿瘤免疫中发挥着重要的作用。随着分子生物学、免疫学、基因工程技术的发展,各种DC疫苗和DC细胞的治疗应运而生,发展迅速。简要综述了DC的生物学特性、DC与肿瘤发生发展的关系、DC抗原的负载方法及其在临床实验中的应用,以为进一步的基础研究和临床实验提供参考。Dendritic cell（DC） is the most powerful professional antigen presenting cell. Lots of studies have demonstrated that the DC vaccine play an important role in antitumor immunity. With the developments of molecular biology, immunology and genetic engineering, rapid progress has been made in DC vaccines and application of DC-based immunotherapy. In this review, the DC biology property, the relation between development of cancer and DC, the production of DC tumor vaccines and their use in clinical trials were discused. It may provide valuable information with respect to DC primary study and clinical trials.

关 键 词：树突状细胞 肿瘤 免疫治疗 

分 类 号：R392.1[医药卫生—免疫学]